Table 3.

Histopathologic and immunohistochemical features of 26 PPMSSs

Case NO.	Subtype	Grade (FNCLCC)	Mitotic Rate (/10HPF)	TLE1	ki-67	EMA	CD99	CK7	Bcl2	cytokeratin	CD34	S-100
1	MFSS	2	7	-	50 %	-	-	-	+	+	-	-
2	MFSS	3	36	2+	35 %	+	+	+	+	+	ND	-
3	MFSS	2	2	3+	6 %	+	-	+	+	+	ND	-
4	PDSS	3	12	2+	ND	+	+	-	+	+	-	+
5	MFSS	NA	2/3HPF	2+	ND	+	+	ND	ND	+	-	-
6	MFSS	3	12	3+	4 %	+	-	-	+	+	ND	-
7	MFSS	2	14	2+	35 %	+	+	+	+	+	-	+
8	MFSS	2	2	3+	10 %	+	-	-	+	+	-	-
9	MFSS	3	2	1+	10 %	+	-	+	+	-	+	-
10	MFSS	2	9	-	ND	+	+	-	+	-	-	-
11	MFSS	2	8	2+	25 %	+	-	+	+	-	ND	+
12	MFSS	2	6	ND	30 %	+	+	ND	-	+	-	-
13	MFSS	2	4	1+	20 %	+	+	+	+	-	-	ND
14	MFSS	2	5	2+	25 %	+	+	+	+	+	-	-
15	MFSS	2	4	2+	60 %	+	-	+	+	+	-	ND
16	MFSS	NA	2/8HPF	3+	40 %	+	+	+	+	-	-	-
17	PDSS	3	21	3+	40 %	+	+	-	+	-	-	-
18	MFSS	2	17	1+	30 %	+	-	ND	ND	+	-	-
19	MFSS	3	12	3+	75 %	+	+	-	+	-	-	-
20	MFSS	2	8	3+	20 %	-	+	-	+	+	-	+
21	MFSS	2	6	2+	35 %	-	ND	ND	+	ND	-	-
22	MFSS	3	21	3+	45 %	+	-	ND	ND	+	-	-
23	MFSS	2	2	2+	45 %	+	-	ND	+	+	-	-
24	MFSS	3	11	3+	55 %	-	-	ND	+	-	-	-
25	BSS	2	4	3+	20 %	+	+	+	+	+	ND	ND
26	PDSS	3	21	ND	20 %	+	+	ND	+	+	ND	+

Abbreviation: NA not available, ND not done, MFSS monophasic fibrous synovial sarcoma, BSS biphasic synovial sarcoma, PDSS poorly differentiated synovial sarcoma, HPF high power field, “+” positive, “-” negative